Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis

Diabetes Technology and Therapeutics

Volumn 19, Issue 11, 2017, Pages 685-691

  Brown, Ruth E ^a   Gupta, Nikhil ^a   Aronson, Ronnie ^a  

^a LMC DIABETES AND ENDOCRINOLOGY   (Canada)

Author keywords

Dapagliflozin; Hemoglobin A1c; Real world evidence; Retrospective analysis; Tertiary healthcare; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; COLESEVELAM; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CANADA; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DISEASE REGISTRY; DIURETIC THERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANALYSIS; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECT; PATHOPHYSIOLOGY; REGISTER;

AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANADA; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85034087872     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2017.0134     Document Type: Article

References (20)

1. Canadian Diabetes Association: 2015 Report on Diabetes: Driving Change. Toronto, ON: CDA, 2015.
2. 2013 Canaidan Diabetes Association Clinical Practice Guidelines Executive Committee: Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2013;37:S1-S212.
3. List JF, Tang W, Woo V, et al.: Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657.
4. Ferrannini E, Jiminez Ramos S, Salsali A, et al.: Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlle, phase 3 trial. Diabetes Care 2010;33:2217-2224.
5. Bailey CJ, Gross JL, Pieters A, et al.: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, doubleblind, placebo-controlled trial. Lancet 2010;375:2223-2233.
6. Strojek K, Yoon KH, Hruba V, et al.: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-938.
7. Jabbour SA, Hardy E, Sugg J, et al.: Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, doubleblind, placebo-controlled study. Diabetes Care 2014;37: 740-750.
8. Bolinder J, Ljunggren O, Johansson L, et al.: Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014;16:159-169.
9. Buysman EK, Chow W, Henk HJ, et al.: Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocr Disord 2015;15:67.
10. Meckley LM, Miyasato G, Kokkotos F, et al.: An observational study of glycemic control in canagliflozin treated patients. Curr Med Res Opin 2015;31:1479-1486.
11. Thayer S, Chow W, Korrer S, et al.: Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin 2016;32:1087-1096.
12. Kosiborod M, Cavender MA, Fu AZ, et al.: Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVDREAL Study. Circulation 2017;136:249-259.
13. Aronson R, Orzech N, Ye C, et al.: Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes : insights into the functionally refractory patient from the LMC Diabetes Registry database. J Diabetes 2016; 8:76-85.
14. Liakos A, Karagiannis T, Bekiari E, et al.: Update on longtermefficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv EndocrinolMetab 2015;6:61-67.
15. Matthaei S, Bowering K, Rohwedder K, et al.: Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab 2015;17:1075-1084.
16. Leiter LA, Berard L, Bowering CK, et al.: Type 2 diabetes mellitus management in Canada : is it improving ?. Can J Diabetes 2013;37:82-89.
17. Wilding J, Bailey C, Rigney U, et al.: Glycated hemoglobin, body weight and blood pressure in type 2 diabetes patients initiating dapagliflozin treatment in primary care: a retrospective study. Diabetes Ther 2016;7:695-711.
18. Mcgovern AP, Dutta N, Munro N, et al.: Dapagliflozin: clinical practice compared with pre-registration trial data. Br J Diabetes Vasc Dis 2014;14:138-143.
19. Zhang L, Feng Y, List J, et al.: Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510-516.
20. Sjostrom CD, Hashemi M, Sugg J, et al.: Dapagliflozininduced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab 2015;17: 809-812.